Expect continued near-term pressure as the market absorbs the announced (but not yet priced) equity offering. Watch for the final prospectus supplement with offering size, price, and pricing date; the stock is likely to trade off the reference price of $26.26 until terms are set. Gilead's non-binding interest provides a modest backstop but no floor. Biotech equity offerings typically trade down 3-7% on announcement of a sizable deal; given this is preliminary, the full impact awaits the final pricing.
Price Chart
Executive Summary
Assembly Biosciences (ASMB) filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants under its existing $400M shelf. The offering size and price remain blank (preliminary filing), but the filing confirm dilution to existing holders. Net proceeds are slated for clinical development and general corporate purposes. Gilead Sciences has expressed non-binding interest to participate pro rata.
Key Facts
- Preliminary prospectus supplement for an underwritten offering of common stock and pre-funded warrants; size and price not yet disclosed.
- Offering under $400M shelf registration (S-3 filed Mar 19, 2026).
- Net proceeds to fund clinical development and general corporate purposes.
- Gilead Sciences indicated non-binding interest to purchase shares pro rata to its ownership percentage.
- Net tangible book value as of Mar 31, 2026 was $198.6M ($12.50/share) on 15,892,353 shares outstanding.
- Offering will cause 'immediate and substantial dilution' per the risk factors section.
- Pre-funded warrants exercisable at $0.001/share, no public trading market expected.
- Underwriters have a 30-day option to purchase additional shares.
- 90-day lock-up on the company and directors/officers.
- Last reported sale price on May 20, 2026 was $26.26 per share.
Financial Impact
Offering size not yet disclosed; based on $26.26 reference price and existing 15.9M shares outstanding, even a modest $50M offering would add ~15-20% dilution. Immediate dilution per share will be substantial (offering price above $12.50 book value).
Risk Factors
- Undisclosed offering size could be larger than expected, increasing dilution.
- Gilead's non-binding indication may not materialize or may be at a discount.
- No public market for pre-funded warrants, limiting liquidity for those instruments.
- Current holders face immediate and substantial dilution as stated in the filing.
- Biotech is pre-revenue, relying on clinical pipeline milestones; capital raises dilute without near-term catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-236812 |
| Document: 0001193125-26-236812-index-headers.html | 0001193125-26-236812 |
| Document: 0001193125-26-236812-index.html | 0001193125-26-236812 |
| Document: 0001193125-26-236812.txt | 0001193125-26-236812 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 10w ago | Institutional Cluster | $30.01 $35.28 | ▲ +17.56% | ▲ +18.75% | $20.30 (−32.36%) |
Aug 13, 2026 10w ago | Press Release | $32.95 $34.38 | ▲ +4.34% | ▲ +5.71% | $20.30 (−38.39%) |
Jun 11, 2026 19w ago | Institutional Cluster | $22.53 $24.15 | ▲ +7.19% | ▲ +6.76% | $20.30 (−9.90%) |
Jun 5, 2026 20w ago | 8-K | $22.56 $23.34 | ▲ +3.48% | ▲ +1.37% | $20.30 (−10.00%) |
May 22, 2026 22w ago | 424B5 | $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $20.30 (+29.39%) |
May 22, 2026 22w ago | 8-K | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 22, 2026 22w ago | Press Release | $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $20.30 (−28.37%) |
May 7, 2026 24w ago | Press Release | $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $20.30 (−31.74%) |
Mar 30, 2026 30w ago | EFFECT | $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $20.30 (−23.80%) |
Mar 19, 2026 31w ago | Press Release | $28.46 $27.70 | ▼ −2.67% | ▼ −0.52% | $20.30 (−28.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers